242 related articles for article (PubMed ID: 23755206)
21. Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models.
Capasso A; Pitts TM; Klauck PJ; Bagby SM; Westbrook L; Kaplan J; Soleimani M; Spreafico A; Tentler JJ; Diamond JR; Arcaroli JJ; Messersmith WA; Eckhardt SG; Leong S
Anticancer Drugs; 2018 Oct; 29(9):827-838. PubMed ID: 30048249
[TBL] [Abstract][Full Text] [Related]
22. SB365 inhibits angiogenesis and induces apoptosis of hepatocellular carcinoma through modulation of PI3K/Akt/mTOR signaling pathway.
Hong SW; Jung KH; Lee HS; Choi MJ; Son MK; Zheng HM; Hong SS
Cancer Sci; 2012 Nov; 103(11):1929-37. PubMed ID: 22909393
[TBL] [Abstract][Full Text] [Related]
23. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.
Xie C; Wan X; Quan H; Zheng M; Fu L; Li Y; Lou L
Cancer Sci; 2018 Apr; 109(4):1207-1219. PubMed ID: 29446853
[TBL] [Abstract][Full Text] [Related]
24. Suppression of tumor proliferation and angiogenesis of hepatocellular carcinoma by HS-104, a novel phosphoinositide 3-kinase inhibitor.
Jung KH; Zheng HM; Jeong Y; Choi MJ; Lee H; Hong SW; Lee HS; Son MK; Lee S; Hong S; Hong SS
Cancer Lett; 2013 Jan; 328(1):176-87. PubMed ID: 22902995
[TBL] [Abstract][Full Text] [Related]
25. Sprengerinin C exerts anti-tumorigenic effects in hepatocellular carcinoma via inhibition of proliferation and angiogenesis and induction of apoptosis.
Zeng KW; Li N; Dong X; Ma ZZ; Jiang Y; Jin HW; Tu PF
Eur J Pharmacol; 2013 Aug; 714(1-3):261-73. PubMed ID: 23684542
[TBL] [Abstract][Full Text] [Related]
26. Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer.
Huynh H; Ong R; Zopf D
J Exp Clin Cancer Res; 2015 Oct; 34():132. PubMed ID: 26514182
[TBL] [Abstract][Full Text] [Related]
27. Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma.
Lai YL; Wang KH; Hsieh HP; Yen WC
J Biomed Sci; 2022 Jan; 29(1):5. PubMed ID: 35062934
[TBL] [Abstract][Full Text] [Related]
28. Combined inhibitory effects of celecoxib and fluvastatin on the growth of human hepatocellular carcinoma xenografts in nude mice.
Gao J; Jia WD; Li JS; Wang W; Xu GL; Ma JL; Ge YS; Yu JH; Ren WH; Liu WB; Zhang CH
J Int Med Res; 2010; 38(4):1413-27. PubMed ID: 20926014
[TBL] [Abstract][Full Text] [Related]
29. DCT015, a new sorafenib derivate, inhibits tumor growth and angiogenesis in gastric cancer models.
Wang W; Wang H; Ni Y; Yao Z; Ye L; Tian J
Tumour Biol; 2016 Jul; 37(7):9221-32. PubMed ID: 26768619
[TBL] [Abstract][Full Text] [Related]
30. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
31. MEK inhibition by cobimetinib suppresses hepatocellular carcinoma and angiogenesis in vitro and in vivo.
Tong X; Wang Q; Wu D; Bao L; Yin T; Chen H
Biochem Biophys Res Commun; 2020 Feb; 523(1):147-152. PubMed ID: 31836141
[TBL] [Abstract][Full Text] [Related]
32. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
[TBL] [Abstract][Full Text] [Related]
33. Antitumor and Antiangiogenic Activities of Lenvatinib in Mouse Xenograft Models of Vascular Endothelial Growth Factor-Induced Hypervascular Human Hepatocellular Carcinoma.
Adachi Y; Matsuki M; Watanabe H; Takase K; Kodama K; Matsui J; Funahashi Y; Nomoto K
Cancer Invest; 2019; 37(4-5):185-198. PubMed ID: 31006280
[TBL] [Abstract][Full Text] [Related]
34. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
[TBL] [Abstract][Full Text] [Related]
35. Novel Aurora/vascular endothelial growth factor receptor dual kinase inhibitor as treatment for hepatocellular carcinoma.
Nakao K; Tanaka S; Miura T; Sato K; Matsumura S; Aihara A; Mitsunori Y; Ban D; Ochiai T; Kudo A; Arii S; Tanabe M
Cancer Sci; 2015 Aug; 106(8):1016-22. PubMed ID: 26011703
[TBL] [Abstract][Full Text] [Related]
36. The epigallocatechin gallate derivative Y
Liao ZH; Zhu HQ; Chen YY; Chen RL; Fu LX; Li L; Zhou H; Zhou JL; Liang G
J Ethnopharmacol; 2020 Sep; 259():112852. PubMed ID: 32278759
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells.
Sbenati RM; Zaraei SO; El-Gamal MI; Anbar HS; Tarazi H; Zoghbor MM; Mohamood NA; Khakpour MM; Zaher DM; Omar HA; Alach NN; Shehata MK; El-Gamal R
Eur J Med Chem; 2021 Jan; 210():113081. PubMed ID: 33310290
[TBL] [Abstract][Full Text] [Related]
38. IPD-196, a novel phosphatidylinositol 3-kinase inhibitor with potent anticancer activity against hepatocellular carcinoma.
Lee JH; Lee H; Yun SM; Jung KH; Jeong Y; Yan HH; Hong S; Hong SS
Cancer Lett; 2013 Feb; 329(1):99-108. PubMed ID: 23142281
[TBL] [Abstract][Full Text] [Related]
39. The in vivo antitumor effects of type I-interferon against hepatocellular carcinoma: the suppression of tumor cell growth and angiogenesis.
Enomoto H; Tao L; Eguchi R; Sato A; Honda M; Kaneko S; Iwata Y; Nishikawa H; Imanishi H; Iijima H; Tsujimura T; Nishiguchi S
Sci Rep; 2017 Sep; 7(1):12189. PubMed ID: 28939881
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of a multi-kinase inhibitor KRC-108 as an anti-tumor agent in vitro and in vivo.
Han SY; Lee CO; Ahn SH; Lee MO; Kang SY; Cha HJ; Cho SY; Ha JD; Ryu JW; Jung H; Kim HR; Koh JS; Lee J
Invest New Drugs; 2012 Apr; 30(2):518-23. PubMed ID: 21080208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
